- Home
- UFCS vs QURE Comparison
UFCS vs QURE Comparison
Compare UFCS & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | QURE |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.4M | 1.1B |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | UFCS | QURE |
|---|---|---|
| Price | $39.67 | $18.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $40.50 | ★ $44.92 |
| AVG Volume (30 Days) | 81.1K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 87.45 | 29.67 |
| EPS | ★ 4.48 | N/A |
| Revenue | ★ $1,386,412,000.00 | $13,107,000.00 |
| Revenue This Year | $11.80 | $126.12 |
| Revenue Next Year | $8.77 | $200.43 |
| P/E Ratio | $9.02 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $25.81 | $8.73 |
| 52 Week High | $40.79 | $71.50 |
Technical Indicators
Market Signals| Indicator | UFCS | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 54.81 |
| Support Level | $35.78 | $13.47 |
| Resistance Level | $40.63 | $18.37 |
| Average True Range (ATR) | 0.96 | 1.43 |
| MACD | 0.19 | 0.30 |
| Stochastic Oscillator | 74.28 | 80.23 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.